Get to know our clinical trials

Ensayo clínico de MCLA-129 en pacientes con CPNM avanzado y otros tumores sólidos

THE GOAL OF THIS STUDY IS TO FIND OUT THE POSSIBLE SIDE EFFECTS OF THE STUDY DRUG, WHETHER THE STUDY DRUG CAN STOP THE GROWTH OR SPREAD OF CANCER CELLS IN YOUR BODY, HOW YOUR BODY PROCESSES THE STUDY DRUG, AND HOW CERTAIN BIOMARKERS OR SMALL SUBSTANCES IN YOUR BODY CHANGE IN RESPONSE TO THE STUDY DRUG.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE I/II STEP-UP AND DOSE-ESCALATION STUDY TO EVALUATE MCLA-129, A HUMAN ANTI-EGFR AND ANTI-C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED NSCLC AND OTHER SOLID TUMORS
  • Code EudraCT: .
  • Protocol number: MCLA-129-CL01
  • Promoter: Merus N.V.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.